These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17931870)

  • 1. Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro.
    Niu C; Yin J; Zhang J; Vederas JC; James MN
    Bioorg Med Chem; 2008 Jan; 16(1):293-302. PubMed ID: 17931870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
    Lee CC; Kuo CJ; Ko TP; Hsu MF; Tsui YC; Chang SC; Yang S; Chen SJ; Chen HC; Hsu MC; Shih SR; Liang PH; Wang AH
    J Biol Chem; 2009 Mar; 284(12):7646-55. PubMed ID: 19144641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides.
    Du Q; Wang S; Jiang Z; Gao W; Li Y; Wei D; Chou KC
    Med Chem; 2005 May; 1(3):209-13. PubMed ID: 16787316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
    Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
    J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of wide-spectrum inhibitors targeting coronavirus main proteases.
    Yang H; Xie W; Xue X; Yang K; Ma J; Liang W; Zhao Q; Zhou Z; Pei D; Ziebuhr J; Hilgenfeld R; Yuen KY; Wong L; Gao G; Chen S; Chen Z; Ma D; Bartlam M; Rao Z
    PLoS Biol; 2005 Oct; 3(10):e324. PubMed ID: 16128623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
    Xiong B; Gui CS; Xu XY; Luo C; Chen J; Luo HB; Chen LL; Li GW; Sun T; Yu CY; Yue LD; Duan WH; Shen JK; Qin L; Shi TL; Li YX; Chen KX; Luo XM; Shen X; Shen JH; Jiang HL
    Acta Pharmacol Sin; 2003 Jun; 24(6):497-504. PubMed ID: 12791174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.
    Ghosh AK; Gong G; Grum-Tokars V; Mulhearn DC; Baker SC; Coughlin M; Prabhakar BS; Sleeman K; Johnson ME; Mesecar AD
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5684-8. PubMed ID: 18796354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
    Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
    Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.
    Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R
    Science; 2003 Jun; 300(5626):1763-7. PubMed ID: 12746549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
    Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.
    Kaeppler U; Stiefl N; Schiller M; Vicik R; Breuning A; Schmitz W; Rupprecht D; Schmuck C; Baumann K; Ziebuhr J; Schirmeister T
    J Med Chem; 2005 Nov; 48(22):6832-42. PubMed ID: 16250642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
    Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
    ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.